Hikma raises full-year revenue outlook on high doxycycline sales
Aug 21 (Reuters) - Hikma Pharmaceuticals said it expected full-year revenue to rise 20 percent as strong sales of its generic antibiotic doxycycline in the United States continue and reported a 93 percent jump in first-half profit.
The company, which makes and sells branded and generic drugs, said profit before tax rose to $111.6 million in the six months ended June 30, from $57.8 million a year earlier.
On an adjusted basis, Hikma's pretax profit rose 158 percent.
Revenue increased 20 percent to $638.3 million.
Hikma shares closed at 1090 pence on Tuesday on the London Stock Exchange.
- Target says data from 40 million cards stolen in November-December
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Facebook, Zuckerberg, banks must face IPO lawsuit: judge
- As Modi storms into India's election, a quiet alternative emerges
- Special Report: Why Ukraine spurned the EU and embraced Russia